268 related articles for article (PubMed ID: 28387100)
1. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
[TBL] [Abstract][Full Text] [Related]
2. [DPP-4 or SGLT2 inhibitor added to metformin alone in type 2 diabetes].
Paquot N; Scheen AJ
Rev Med Suisse; 2017 Aug; 13(571):1410-1415. PubMed ID: 28837277
[TBL] [Abstract][Full Text] [Related]
3. [How I treat...The choice between a sulphonylulrea and a gliptin to manage hyperglycaemia in type 2 diabetes].
Scheen AJ
Rev Med Liege; 2014 Sep; 69(9):476-84. PubMed ID: 25796755
[TBL] [Abstract][Full Text] [Related]
4. [How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES].
Scheen AJ
Rev Med Liege; 2015 Dec; 70(12):593-9. PubMed ID: 26867302
[TBL] [Abstract][Full Text] [Related]
5. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
[TBL] [Abstract][Full Text] [Related]
6. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
Avogaro A; Delgado E; Lingvay I
Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
[TBL] [Abstract][Full Text] [Related]
7. [Optimizing basal insulin therapy in type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2017 Mar; 72(3):156-161. PubMed ID: 28387494
[TBL] [Abstract][Full Text] [Related]
8. [Gliptin-gliflozin combination for treating type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Suisse; 2016 Aug; 12(527):1384-1388. PubMed ID: 28671793
[TBL] [Abstract][Full Text] [Related]
9. [Use of oral glucose-lowering agents in patients with renal impairment].
Scheen AJ; Paquot N
Rev Med Liege; 2017 Oct; 72(10):462-468. PubMed ID: 29058840
[TBL] [Abstract][Full Text] [Related]
10. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
11. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1407-1417. PubMed ID: 27435042
[TBL] [Abstract][Full Text] [Related]
12. [How I manage a patient with type 2 diabetes not well controlled with a metformin plus gliptin combination].
Scheen AJ
Rev Med Liege; 2019 Sep; 74(9):443-450. PubMed ID: 31486312
[TBL] [Abstract][Full Text] [Related]
13. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
14. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
15. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
16. Oral combination therapy in primary care.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
[TBL] [Abstract][Full Text] [Related]
17. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.
Fitchett DH; Udell JA; Inzucchi SE
Eur J Heart Fail; 2017 Jan; 19(1):43-53. PubMed ID: 27653447
[TBL] [Abstract][Full Text] [Related]
18. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
McReelis KD; Lovshin JA
Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
[No Abstract] [Full Text] [Related]
19. [Which place to be reserved to sulphonylureas and which precautions to be taken ?].
Scheen AJ
Rev Med Liege; 2021 Jan; 76(1):7-12. PubMed ID: 33443322
[TBL] [Abstract][Full Text] [Related]
20. Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.
DeFilippis EM; Givertz MM
Curr Heart Fail Rep; 2016 Jun; 13(3):111-8. PubMed ID: 27188181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
